<DOC>
	<DOCNO>NCT02710526</DOCNO>
	<brief_summary>Phase II , open label , randomize , two treatment group study design evaluate steady state pharmacokinetics buprenorphine norbuprenorphine follow repeat subcutaneous administration CAM2038 .</brief_summary>
	<brief_title>Phase II Pharmacokinetics Study CAM2038</brief_title>
	<detailed_description>This phase II , open label , randomize , two treatment group study design evaluate steady state pharmacokinetics buprenorphine norbuprenorphine follow repeat subcutaneous administration CAM2038 weekly different injection site evaluate steady state pharmacokinetics buprenorphine norbuprenorphine repeat subcutaneous administration CAM2038 monthly opioid dependent subject history chronic non cancer pain . The study involve three phase : Screening , Treatment , Follow .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Subject must provide write informed consent prior conduct study related procedure . 2 . Male non pregnant , non lactate female subject , age 19 65 year , inclusive . 3 . Body mass index 19 35 kg/m2 , inclusive . 4 . Current diagnosis moderate severe opioid use disorder ( accord DSM 5 ) past medical history opioid use disorder currently treat SL BPN . 5 . Subject must take SL BPN ( SubutexÂ® equivalent ) 24 mg daily least 30 day prior Screening . 6 . Subject history moderate severe chronic non cancer pain . 1 . Individuals meet DSM 5 substance use disorder criterion alcohol , benzodiazepine , central nervous system ( CNS ) stimulant , drug abuse ( exclude caffeine , tobacco THC/marijuana ) . 2 . Any clinically significant abnormality basis medical history , vital sign , physical examination , 12 lead electrocardiogram laboratory evaluation 3 . Use ( therapeutic non therapeutic ) opioids SL BPN . 4 . Aspartate aminotransferase ( AST ) level &gt; 3 X upper limit normal , alanine aminotransferase ( ALT ) , level &gt; 3 X upper limit normal , total bilirubin &gt; 1.5 X upper limit normal , creatinine &gt; 1.5 X upper limit normal . 5 . Pregnant lactate plan become pregnant study . 6 . Diagnosis , currently investigation , fibromyalgia , complex regional pain syndrome , neurogenic claudication due spinal stenosis , spinal cord compression , acute nerve root compression , severe progressive low extremity weakness numbness . 7 . History chemotherapy confirm malignancy ( except basal cell squamous carcinoma skin ) within past 2 year . 8 . Clinically significant history , current evidence , suicidal ideation actively suicidal , base Columbia Suicide Severity Rating Scale ( C SSRS ; grade 4 5 ) . 9 . Clinically significant history major depressive disorder poorly control medication . 10 . Hypersensitivity allergy BPN opioids , excipients CAM2038 . 11 . Exposure investigational drug within 4 week prior Screening . 12 . Participants clinically significant history risk factor Torsades de Pointes exist ventricular tachyarrhythmias bigeminy , trigeminy , heart failure , hypokalemia , family history Long QT Syndrome . 13 . Requires current use agent potential prolong QTc interval . 14 . Requires current use agent strong inhibitor inducer cytochrome P450 3A4 ( CYP3A4 ) azole antifungal ( e.g. , ketoconazole ) , macrolide antibiotic ( e.g. , clarithromycin ) , protease inhibitor ( e.g. , ritonavir , indinavir , saquinavir ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>